Last reviewed · How we verify
NCT07052617: KARMA
Impact of Different CRRT Modalities, Dosing Strategies, and Timing on Kidney Recovery and Prolonged Kidney Dysfunction
trial testing Continuos renal replacement therapy in Acute Kidney Disease in 2,500 participants. Not yet recruiting.
25 September 2026
Quick facts
| Lead sponsor | Croatian Society for Organ Support |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 2,500 |
| Start date | 25 September 2025 |
| Primary completion | 25 September 2026 |
| Estimated completion | 25 December 2026 |
Drugs / interventions tested
- Continuos renal replacement therapy
Conditions studied
- Acute Kidney Disease — all drugs for Acute Kidney Disease →
- Acute Kidney Injury — all drugs for Acute Kidney Injury →
Sponsor
Croatian Society for Organ Support
Who can join
18 and older, any sex, with Acute Kidney Disease or Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
KARMA study is a hospital-based research study looking at how different ways of delivering kidney support therapy (CRRT) affect patients who are critically ill. In some cases, the kidneys may temporarily stop working in very sick patients, and machines are used to filter the blood. This study is exploring whether the way the investigators use these machines - how early to start, how much treatment to give, and what type to choose - makes a difference in how well the kidneys recover. By learning from many hospitals and hundreds of patients, KARMA hopes to improve treatment choices and help patients regain their kidney function faster.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07052617
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Kidney Disease
Currently open trials in the same condition.
- NCT07182422 — AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease · Phase 4 · recruiting
- NCT05325099 — Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum · Phase 1, PHASE2 · recruiting
Other Croatian Society for Organ Support trials
Trials by the same sponsor.
- NCT05608096 — European Registry for Hemadsorption in Sepsis With the Seraph Filter · unknown
- NCT05470907 — Registry for Hemoperfusion of Covid-19 ICU Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07052617 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Croatian Society for Organ Support
- Last refreshed: 4 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07052617.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing